|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TAF6L |
Gene summary for TAF6L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TAF6L | Gene ID | 10629 |
| Gene name | TATA-box binding protein associated factor 6 like | |
| Gene Alias | PAF65A | |
| Cytomap | 11q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A024R5A7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10629 | TAF6L | LZE22T | Human | Esophagus | ESCC | 4.70e-03 | 2.15e-01 | 0.068 |
| 10629 | TAF6L | LZE24T | Human | Esophagus | ESCC | 8.06e-09 | 2.38e-01 | 0.0596 |
| 10629 | TAF6L | P1T-E | Human | Esophagus | ESCC | 8.60e-09 | 3.06e-01 | 0.0875 |
| 10629 | TAF6L | P2T-E | Human | Esophagus | ESCC | 6.47e-16 | 3.48e-01 | 0.1177 |
| 10629 | TAF6L | P4T-E | Human | Esophagus | ESCC | 5.68e-26 | 4.79e-01 | 0.1323 |
| 10629 | TAF6L | P5T-E | Human | Esophagus | ESCC | 9.56e-08 | 1.80e-01 | 0.1327 |
| 10629 | TAF6L | P8T-E | Human | Esophagus | ESCC | 8.06e-13 | 2.31e-01 | 0.0889 |
| 10629 | TAF6L | P9T-E | Human | Esophagus | ESCC | 3.92e-17 | 3.07e-01 | 0.1131 |
| 10629 | TAF6L | P10T-E | Human | Esophagus | ESCC | 1.15e-16 | 1.39e-01 | 0.116 |
| 10629 | TAF6L | P11T-E | Human | Esophagus | ESCC | 8.78e-05 | 2.58e-01 | 0.1426 |
| 10629 | TAF6L | P12T-E | Human | Esophagus | ESCC | 4.49e-20 | 2.97e-01 | 0.1122 |
| 10629 | TAF6L | P15T-E | Human | Esophagus | ESCC | 1.87e-03 | 9.15e-02 | 0.1149 |
| 10629 | TAF6L | P16T-E | Human | Esophagus | ESCC | 5.67e-17 | 2.34e-01 | 0.1153 |
| 10629 | TAF6L | P17T-E | Human | Esophagus | ESCC | 9.08e-05 | 2.31e-01 | 0.1278 |
| 10629 | TAF6L | P20T-E | Human | Esophagus | ESCC | 1.35e-09 | 2.01e-01 | 0.1124 |
| 10629 | TAF6L | P21T-E | Human | Esophagus | ESCC | 7.31e-14 | 2.87e-01 | 0.1617 |
| 10629 | TAF6L | P22T-E | Human | Esophagus | ESCC | 2.02e-06 | 1.37e-01 | 0.1236 |
| 10629 | TAF6L | P23T-E | Human | Esophagus | ESCC | 1.18e-20 | 4.12e-01 | 0.108 |
| 10629 | TAF6L | P24T-E | Human | Esophagus | ESCC | 8.84e-05 | 1.19e-01 | 0.1287 |
| 10629 | TAF6L | P26T-E | Human | Esophagus | ESCC | 9.35e-10 | 1.79e-01 | 0.1276 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
| GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
| GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
| GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
| GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
| GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
| GO:009872714 | Esophagus | ESCC | maintenance of cell number | 90/8552 | 134/18723 | 3.94e-07 | 5.43e-06 | 90 |
| GO:001982714 | Esophagus | ESCC | stem cell population maintenance | 88/8552 | 131/18723 | 5.23e-07 | 6.97e-06 | 88 |
| GO:00063673 | Esophagus | ESCC | transcription initiation from RNA polymerase II promoter | 56/8552 | 77/18723 | 1.30e-06 | 1.59e-05 | 56 |
| GO:000635211 | Esophagus | ESCC | DNA-templated transcription, initiation | 86/8552 | 130/18723 | 1.88e-06 | 2.19e-05 | 86 |
| GO:00708973 | Esophagus | ESCC | transcription preinitiation complex assembly | 30/8552 | 36/18723 | 3.60e-06 | 3.95e-05 | 30 |
| GO:00439662 | Esophagus | ESCC | histone H3 acetylation | 43/8552 | 61/18723 | 7.57e-05 | 5.67e-04 | 43 |
| GO:00511232 | Esophagus | ESCC | RNA polymerase II preinitiation complex assembly | 18/8552 | 24/18723 | 3.43e-03 | 1.41e-02 | 18 |
| GO:20000361 | Esophagus | ESCC | regulation of stem cell population maintenance | 23/8552 | 33/18723 | 4.57e-03 | 1.78e-02 | 23 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa030222 | Esophagus | ESCC | Basal transcription factors | 35/4205 | 45/8465 | 1.01e-04 | 4.06e-04 | 2.08e-04 | 35 |
| hsa0302211 | Esophagus | ESCC | Basal transcription factors | 35/4205 | 45/8465 | 1.01e-04 | 4.06e-04 | 2.08e-04 | 35 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TAF6L | SNV | Missense_Mutation | c.1132N>A | p.Glu378Lys | p.E378K | Q9Y6J9 | protein_coding | tolerated(0.1) | possibly_damaging(0.899) | TCGA-AC-A6NO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TAF6L | SNV | Missense_Mutation | c.1201N>T | p.Leu401Phe | p.L401F | Q9Y6J9 | protein_coding | tolerated(0.1) | benign(0.36) | TCGA-BH-A0DP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| TAF6L | SNV | Missense_Mutation | novel | c.1018N>A | p.Val340Met | p.V340M | Q9Y6J9 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| TAF6L | deletion | Frame_Shift_Del | novel | c.557delA | p.Asn186ThrfsTer18 | p.N186Tfs*18 | Q9Y6J9 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| TAF6L | SNV | Missense_Mutation | c.762N>G | p.Ile254Met | p.I254M | Q9Y6J9 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| TAF6L | SNV | Missense_Mutation | c.1775N>G | p.Ser592Trp | p.S592W | Q9Y6J9 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.894) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TAF6L | SNV | Missense_Mutation | c.1068N>G | p.His356Gln | p.H356Q | Q9Y6J9 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| TAF6L | SNV | Missense_Mutation | c.1775N>G | p.Ser592Trp | p.S592W | Q9Y6J9 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.894) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| TAF6L | SNV | Missense_Mutation | rs759238822 | c.673N>T | p.Arg225Cys | p.R225C | Q9Y6J9 | protein_coding | tolerated(0.13) | benign(0.424) | TCGA-AA-3684-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| TAF6L | SNV | Missense_Mutation | c.235N>A | p.Ala79Thr | p.A79T | Q9Y6J9 | protein_coding | tolerated(0.15) | benign(0.012) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |